Zhifei Biotech announced that the clinical trial application for the nasal spray recombinant respiratory syncytial virus vaccine developed by Zhifei Luzhu, a wholly-owned subsidiary, has been accepted by the State Drug Administration. The acceptance number is CXSL2600844. If no negative or questioning opinions have been received from the Drug Review Center within 60 days from the date of acceptance, Zhifei Green Bamboo may carry out clinical trials according to the submitted plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.